MUMBAI, India — Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for arformoterol tartrate inhalation solution, 15 mcg/2 mL, Unit-Dose Vials, the generic version of Brovana Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals.
Arformoterol tartrate inhalation solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, N.C., and marks the company’s first nebulizer approval.
Comments are closed.